casopitant   Click here for help

GtoPdb Ligand ID: 5758

Synonyms: GW679769 | Rezonic (proposed trade name) | Zunrisa (proposed trade name)
Compound class: Synthetic organic
Comment: Casopitant is an investigational NK1 receptor antagonist.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 9
Topological polar surface area 47.1
Molecular weight 616.26
XLogP 5.96
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(c(c1)C)C1CC(CCN1C(=O)N(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)C)N1CCN(CC1)C(=O)C
Isomeric SMILES Fc1ccc(c(c1)C)[C@H]1C[C@H](CCN1C(=O)N([C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)C)N1CCN(CC1)C(=O)C
InChI InChI=1S/C30H35F7N4O2/c1-18-13-24(31)5-6-26(18)27-17-25(40-11-9-39(10-12-40)20(3)42)7-8-41(27)28(43)38(4)19(2)21-14-22(29(32,33)34)16-23(15-21)30(35,36)37/h5-6,13-16,19,25,27H,7-12,17H2,1-4H3/t19-,25+,27-/m1/s1
InChI Key XGGTZCKQRWXCHW-WMTVXVAQSA-N
No information available.
Summary of Clinical Use Click here for help
Casopitant has completed Phase 2I clinical trials evaluating its utility as an antiemetic for the treatment of chemotherapy-induced nausea and vomiting. Phase 2 clinical trials for insomnia, major depressive disorder (MDD) and anxiety disorders have also been completed. Click here to link to ClinicalTrials.gov's complete list of casopitant trials, and here to link to GSK's list of clinical trials evaluating this compound (hosted on the GSK clinical study register).